SummaryB cells are an abundant population of lymphocytes that can efficiently capture, process, and present antigen for recognition by activated or memory T cells. Controversial experiments and arguments exist, however, as to whether B cells are or should be involved in the priming of virgin T cells in vivo. Using B cell-deficient mice, we have studied the role of B cells as antigen-presenting cells in a wide variety of tests, including assays of T cell proliferation and cytokine production in responses to protein antigens, T cell killing to minor and major histocompatibility antigens, skin graft rejection, and the in vitro and in vivo responses to shistosome eggs. We found that B cells are not critical for either CD4 or CD8 T cell priming in any of these systems. This finding lends support to the notion that the priming of T cells is reserved for specialized cells such as dendritic cells and that antigen presentation by B cells serves distinct immunological functions.

Background:Globally, pollen allergy is a major public health problem, but a fundamental unknown is the likely impact of climate change. To our knowledge, this is the first study to quantify the consequences of climate change upon pollen allergy in humans.Objectives:We produced quantitative estimates of the potential impact of climate change upon pollen allergy in humans, focusing upon common ragweed (Ambrosia artemisiifolia) in Europe.Methods:A process-based model estimated the change in ragweed’s range under climate change. A second model simulated current and future ragweed pollen levels. These findings were translated into health burdens using a dose–response curve generated from a systematic review and from current and future population data. Models considered two different suites of regional climate/pollen models, two greenhouse gas emissions scenarios [Representative Concentration Pathways (RCPs) 4.5 and 8.5], and three different plant invasion scenarios.Results:Our primary estimates indicated that sensitization to ragweed will more than double in Europe, from 33 to 77 million people, by 2041–2060. According to our projections, sensitization will increase in countries with an existing ragweed problem (e.g., Hungary, the Balkans), but the greatest proportional increases will occur where sensitization is uncommon (e.g., Germany, Poland, France). Higher pollen concentrations and a longer pollen season may also increase the severity of symptoms. Our model projections were driven predominantly by changes in climate (66%) but were also influenced by current trends in the spread of this invasive plant species. Assumptions about the rate at which ragweed spreads throughout Europe had a large influence upon the results.Conclusions:Our quantitative estimates indicate that ragweed pollen allergy will become a common health problem across Europe, expanding into areas where it is currently uncommon. Control of ragweed spread may be an important adaptation strategy in response to climate change.Citation:Lake IR, Jones NR, Agnew M, Goodess CM, Giorgi F, Hamaoui-Laguel L, Semenov MA, Solomon F, Storkey J, Vautard R, Epstein MM. 2017. Climate change and future pollen allergy in Europe. Environ Health Perspect 125:385–391; http://dx.doi.org/10.1289/EHP173

Common ragweed (Ambrosia artemisiifolia) is an invasive alien species in Europe producing pollen that causes severe allergic disease in susceptible individuals 1 . Ragweed plants could further invade European land with climate and land-use changes 2,3 . However, airborne pollen evolution depends not only on plant invasion, but also on pollen production, release and atmospheric dispersion changes. To predict the e ect of climate and land-use changes on airborne pollen concentrations, we used two comprehensive modelling frameworks accounting for all these factors under high-end and moderate climate and land-use change scenarios. We estimate that by 2050 airborne ragweed pollen concentrations will be about 4 times higher than they are now, with a range of uncertainty from 2 to 12 largely depending on the seed dispersal rate assumptions. About a third of the airborne pollen increase is due to on-going seed dispersal, irrespective of climate change. The remaining two-thirds are related to climate and land-use changes that will extend ragweed habitat suitability in northern and eastern Europe and increase pollen production in established ragweed areas owing to increasing CO 2 . Therefore, climate change and ragweed seed dispersal in current and future suitable areas will increase airborne pollen concentrations, which may consequently heighten the incidence and prevalence of ragweed allergy.Common ragweed is native in North America. Since the end of the nineteenth century it has invaded large regions in Europe 4,5 and also parts of Australia, South America and East Asia 6 . The sensitization of the human population to ragweed pollen is increasing in many countries 7 . In Europe, its established presence is at present largely limited to several areas in the [42 • N-47 • N] latitudinal band (Pannonian plain, northern Italy and southeastern France) and in areas with disturbed land, such as agricultural areas or along roads and railways. However, there is a high potential for further spread given that suitable, although not yet invaded, habitats are substantial 8,9 . Plant density may also further increase in established infested areas. Factors determining the rate of spread of ragweed plants within its current climatic niche include seed dispersal due to natural or anthropogenic processes (for example, spread through contaminated crop seeds), land-use change (which would provide changes in disturbed land areas) and the efficiency of ragweed eradication policies. Climate change may further impact the spread of ragweed by altering the climatic niche determined by physiological thresholds or affecting cropping patterns 5,10,11 . Ragweed airborne pollen concentrations depend not only on plant infestation, but also on phenology, pollen production, release, dispersion and atmospheric transport. Recent modelling efforts 12-15 have led to increasingly successful simulations of airborne pollen concentrations. Although previous work was mostly devoted to short-term forecasts to inform sensitized populations, the maturity of the mode...

Atopic asthma is a chronic inflammatory pulmonary disease characterised by recurrent episodes of wheezy, laboured breathing with an underlying Th2 cell-mediated inflammatory response in the airways. It is currently treated and, more or less, controlled depending on severity, with bronchodilators e.g. long-acting beta agonists and long-acting muscarinic antagonists or anti-inflammatory drugs such as corticosteroids (inhaled or oral), leukotriene modifiers, theophyline and anti-IgE therapy. Unfortunately, none of these treatments are curative and some asthmatic patients do not respond to intense anti-inflammatory therapies. Additionally, the use of long-term oral steroids has many undesired side effects. For this reason, novel and more effective drugs are needed. In this review, we focus on the CD4+ Th2 cells and their products as targets for the development of new drugs to add to the current armamentarium as adjuncts or as potential stand-alone treatments for allergic asthma. We argue that in early disease, the reduction or elimination of allergen-specific Th2 cells will reduce the consequences of repeated allergic inflammatory responses such as lung remodelling without causing generalised immunosuppression.